Monitoring Frequency for Vyvanse Treatment
Patients on Vyvanse should be seen at least monthly until symptoms are stabilized, with weekly contact (in-person or by phone) during initial dose titration, which typically takes 2-4 weeks. 11
Initial Titration Phase (First 2-4 Weeks)
During the initial dose adjustment period, maintain weekly contact with patients, either through office visits or telephone follow-up 11. This frequent monitoring allows for:
- Systematic assessment of target ADHD symptoms through parent, teacher, and self-ratings (for adolescents/adults)
- Evaluation of specific side effects including insomnia, decreased appetite, headaches, social withdrawal, tics, and weight loss
- Objective weight measurement at each visit to monitor appetite suppression
- Dose adjustments as needed based on response and tolerability
Maintenance Phase (After Stabilization)
Once the optimal dose is established and symptoms are controlled, schedule appointments at least monthly until symptoms have been fully stabilized 11. After achieving stable symptom control, visit frequency can be adjusted based on:
- Robustness of treatment response - Poor responders need more frequent monitoring
- Adherence concerns - Patients with compliance issues require closer follow-up
- Side effect burden - Significant adverse effects warrant more frequent visits
- Comorbid psychiatric conditions - Additional mental health problems necessitate increased monitoring
- Diversion risk - Adolescents require particular vigilance for medication misuse 2
Critical Monitoring Elements at Each Visit
At every appointment, systematically assess:
- Target ADHD symptoms using standardized rating scales (ADHD-RS or similar)
- Weight measurement as an objective marker of appetite effects
- Cardiovascular parameters including blood pressure and pulse, as stimulants can cause modest increases 3
- Specific side effects through direct questioning about insomnia, appetite loss, headaches, irritability, and tics
- Prescription refill patterns to identify potential diversion or misuse, especially in adolescents 2
Special Considerations
For adolescents, consider more frequent monitoring due to diversion risks and the need for extended symptom coverage (e.g., while driving) 2. The prodrug formulation of Vyvanse offers some protection against misuse since it requires metabolic activation, but vigilance remains essential.
Common pitfall: Failing to obtain collateral information from teachers or family members. ADHD symptom assessment should never rely solely on patient self-report—always gather ratings from multiple observers across different settings 11.
The evidence consistently supports this structured monitoring approach across all age groups, with more intensive follow-up during titration and when complications arise, transitioning to less frequent but regular monitoring once stable therapeutic benefit is achieved.